



REVIEW ON TREATMENT OF THYROID DISEASE IN PREGNANCY

Shreya Uday Mahajan^{1*}, Prajakta Deepak Suryawanshi², Sneha Kashinath Landge³ and Chaitali Chandrakant Kulkarni⁴

^{1,4}Pharm.D, Swami Ramanand Teerth Marathwada University, Nanded.



*Corresponding Author: Shreya Uday Mahajan

Pharm.D, Swami Ramanand Teerth Marathwada University, Nanded.

Email ID: mahajanshreya2003@gmail.com

Article Received on 20/05/2024

Article Revised on 10/06/2024

Article Accepted on 01/07/2024

ABSTRACT

Pregnancy-related thyroid dysfunction is a serious health issue that can have a negative impact on the health of the mother and the fetus. The goal of this review is to present a thorough examination of the current approaches of treating thyroid dysfunctions, such as thyroiditis, hypothyroidism, and hyperthyroidism, during pregnancy. Antithyroid drugs, such as propylthiouracil (PTU) in the first trimester and methimazole (MMI) later, are commonly used to treat hyperthyroidism, which is defined by an excess of thyroid hormone production. Careful monitoring is required to prevent fetal hypothyroidism or goiter. Levothyroxine is used to treat hypothyroidism, which is characterized by low thyroid hormone levels. This preserves euthyroid condition and promotes the best possible health for both the mother and the fetus. The therapy of thyroiditis varies according to the stage of the illness, frequently necessitating close observation and symptomatic treatment. The significance of routine thyroid function testing and individualized treatment regimens catered to the requirements of each patient is also covered in this study. It also covers the effects of untreated thyroid problems on the course of pregnancy and emphasizes new developments in treatment guidelines. The study emphasizes that in order to maximize care and enhance prognoses for pregnant women with thyroid illness, obstetricians, endocrinologists, and primary care physicians must collaborate across multidisciplinary fields..

KEYWORDS: Thyroid disease, pregnancy, hyperthyroidism, hypothyroidism, thyroiditis, treatment, antithyroid medications, levothyroxine, maternal health, fetal outcomes.

INTRODUCTION

Any thyroid gland malfunction during pregnancy is referred to as thyroid illness, and it can have a serious negative effect on the mother's and the fetus's health. The hormones thyroxine (T4) and triiodothyronine (T3), which are produced by the thyroid gland in the neck, control energy levels, metabolism, and a host of other essential bodily processes. The most common thyroid conditions that arise during pregnancy are thyroiditis (inflammation of the thyroid), hyperthyroidism (overactive thyroid gland), and hypothyroidism (underactive thyroid). It is crucial to identify and treat these diseases during pregnancy because, if left untreated, they can result in a variety of issues.^[1,2]

HISTORICAL CONTEXT OF THYROID DISEASE DURING PREGNANCY

Over the past century, there has been a considerable evolution in our understanding of thyroid dysfunction during pregnancy and how it is managed. The effects of thyroid dysfunction on pregnancy were not well known in the early 20th century, and the lack of certain diagnostic procedures made diagnosis difficult. High

rates of maternal and fetal morbidity and death resulted from the misdiagnosis or lack of diagnosis of thyroid illness in many situations.

Thyroid physiology and its function in pregnancy became better understood in the 1940s and 1950s thanks to developments in endocrinology. More precise diagnostic instruments were made available with the advent of radioactive iodine uptake assays and thyroid function testing, such as serum T4 and T3 assessments. During this time, it became evident that thyroid dysfunction if untreated might result in serious side effects, such as miscarriage, preterm delivery, and fetal development problems.

Sensitive tests for thyroid-stimulating hormone (TSH) were developed in the 1970s and 1980s, marking a significant progress in the field of thyroid disease diagnosis. More sophisticated treatment methods, such as the use of levothyroxine for hypothyroidism and antithyroid drugs for hyperthyroidism, were developed as a result of the realization of how crucial it was to maintain euthyroid state during pregnancy.

Research in the past several decades has concentrated on improving treatment plans to reduce hazards to the mother and the developing fetus. Pregnancy-related thyroid disease screening, diagnosis, and treatment have set guidelines. These include the recommendations of the American Thyroid Association, which stress the value of customized medication regimens, routine thyroid function monitoring, and preconception counseling.^[3,4,5]

EPIDEMIOLOGY OF THYROID DISEASE DURING PREGNANCY

One frequent endocrine condition that can have a big impact on pregnancy outcomes is thyroid illness. Based on factors including iodine level, demographic characteristics, and geographic location, thyroid illness during pregnancy can have different effects and rates.

Prevalence

1. Hypothyroidism

- Approximately 0.3-0.5% of pregnant women have overt hypothyroidism, which is defined by high TSH and low free T4 levels.
- An increased TSH with normal free T4 levels, or subclinical hypothyroidism, is more common and affects around 2-3% of pregnancies. Subclinical hypothyroidism is a crucial area of study in prenatal care since it can still have major effects on pregnancy and fetal development.

2. Hyperthyroidism

- Less often occurring, overt hyperthyroidism (suppressed TSH with high free T4 and/or T3 levels) affects 0.1-0.4% of pregnancies.
- The most frequent cause of hyperthyroidism during pregnancy is the autoimmune condition Graves' disease.

3. Thyroiditis

- Depending on hereditary predispositions and iodine deficiency, postpartum thyroiditis affects 5–10% of women. This syndrome can induce temporary hyperthyroidism followed by hypothyroidism and often manifests during the first year following birth.^[6,7]

Geographic and Demographic Variations

- **Iodine Status:** Especially in underdeveloped nations, iodine deficiency continues to be a serious worldwide health concern. Pregnant women in iodine-deficient areas are more likely to get goiter and hypothyroidism. On the other hand, these disorders are often less common in places with enough iodine.
- **Genetics and Autoimmunity:** Genetic factors can influence the frequency of autoimmune thyroid illnesses, including Graves' disease and Hashimoto's thyroiditis. Thyroid dysfunction during pregnancy may be more common in some groups with greater incidence of autoimmune disorders.

- **Age and Parity:** Thyroid issues are more common in older pregnant women and those with many pregnancies (high parity). Furthermore, the risk of thyroid illness in subsequent pregnancies is increased in those with a history of autoimmune disease or thyroid dysfunction.

Impact on Pregnancy Outcomes

Pregnancy-related thyroid illness is linked to a number of negative consequences, highlighting the significance of early identification and treatment:

- Miscarriage, preterm birth, low birth weight, gestational hypertension, and impaired fetal neurodevelopment are among the complications that hyperthyroidism can cause.
- Preterm birth, low birth weight, pre-eclampsia, and thyroid storm, a potentially fatal condition if left untreated, are among the complications that hyperthyroidism can cause. Maternal antibodies that cross the placenta can also result in fetal hyperthyroidism or hypothyroidism.
- Thyroiditis can alter thyroid hormone levels, which can affect a mother's health and raise her risk of postpartum depression.^[8,9]

NORMAL THYROID FUNCTION AND HORMONE PRODUCTION

Thyroxine (T4) and triiodothyronine (T3), the primary thyroid hormones that control metabolism, energy generation, and general growth and development, are produced by the thyroid gland, which is situated in the neck. Thyrotropin-releasing hormone (TRH) from the brain, which is regulated by thyroid-stimulating hormone (TSH) from the pituitary gland, is responsible for controlling the release of these hormones.

- **Thyroxine (T4):** In peripheral tissues, T4, the main hormone generated by the thyroid, is changed into the more active version, T3.
- **Triiodothyronine (T3):** T3 is the type of thyroid hormone that is physiologically active and affects cellular metabolic processes.
- **Thyroid-Stimulating Hormone (TSH):** TSH causes the thyroid to generate T4 and T3, which are then used in a feedback loop with the pituitary and hypothalamus to keep the body in balance.^[10,11]

CHANGES IN THYROID PHYSIOLOGY DURING PREGNANCY

Thyroid physiology undergoes major modifications throughout pregnancy in order to accommodate the growing fetus's and the mother's higher metabolic needs:

1. Enhanced Production of Thyroid Hormones

- Early in pregnancy, the placenta produces human chorionic gonadotropin (hCG), which activates the thyroid gland because it resembles thyroid-stimulating hormone (TSH) and increases the synthesis of T4 and T3.
- Total T4 and T3 levels are raised when estrogen raises the levels of thyroid-binding globulin (TBG), a protein that carries thyroid hormones in the blood.

However, free hormone levels (free T4 and free T3) stay within the normal range.

2. Iodine Demand

- Because iodine is transferred to the fetus and renal clearance rises during pregnancy, there is an increased requirement for iodine, a crucial component of thyroid hormones. For enhanced thyroid hormone production to be supported, an adequate iodine intake is necessary.

3. Adaptations in Thyroid Regulation

- To preserve a delicate balance and guarantee adequate hormone availability for both maternal and fetal tissues, the feedback control of thyroid hormones is modified.^[12,13]

IMPACT OF PREGNANCY ON THYROID FUNCTION TESTS

Because pregnancy alters hormone levels and protein binding, it can impact how thyroid function tests are interpreted:

1. TSH Levels

- hCG stimulation during the first trimester can suppress TSH levels, frequently resulting in lower-than-normal TSH readings. TSH usually returns to normal as pregnancy goes on.

2. Total T4 and T3

- Elevated TBG levels result in higher concentrations of total T4 and T3. These readings can be as much as 50% more than those that are not pregnant. For appropriate interpretation, reference ranges particular to pregnancy must be used.

3. Free T4 and Free T3

- Although minor fluctuations can happen, free thyroid hormone levels (free T4 and free T3) often stay within the normal range. It is more accurate to measure free hormone levels, particularly free T4, for determining thyroid function during pregnancy.

4. Thyroid Antibodies

- Thyroid peroxidase antibodies (TPOAb) or thyrotropin receptor antibodies (TRAb) may be raised in pregnant women with autoimmune thyroid diseases (e.g., Hashimoto's thyroiditis or Graves' disease), which might affect thyroid function and call for close observation.^[14,15]

TYPES OF THYROID DISEASE IN PREGNANCY

1. Hypothyroidism

The condition known as hypothyroidism in pregnancy is characterized by insufficient thyroid hormone synthesis by the thyroid gland, which raises blood levels of thyroid-stimulating hormone (TSH) and lowers levels of free thyroxine (T4)

- Overt hypothyroidism:** Identified by notably high TSH and low free T4 values.

- Subclinical hypothyroidism:** Usually asymptomatic or with minor symptoms, it is defined by high TSH levels with normal free T4 levels.

2. Hyperthyroidism

Pregnancy-related hyperthyroidism is characterized by the thyroid gland producing too many thyroid hormones, which lowers TSH levels and raises levels of free T4 and/or triiodothyronine (T3)

- Overt hyperthyroidism:** Defined by increased free T4 and/or T3 levels with low or undetectable TSH.
- Subclinical hyperthyroidism:** Characterized by normal free T4 and T3 levels and low TSH levels; usually associated with few or no clinical symptoms.

3. Thyroiditis

Thyroiditis is an inflammation of the thyroid gland that, depending on the stage of the ailment, can result in either temporary hypothyroidism or hyperthyroidism.

- Postpartum Thyroiditis:** An autoimmune thyroiditis that often manifests in the first year following delivery as hyperthyroidism, followed by hypothyroidism and, frequently, a return to euthyroidism.
- Subacute Thyroiditis:** Often referred to as De Quervain's thyroiditis, subacute thyroiditis is typified by excruciating thyroid inflammation and frequently occurs after a viral illness.

4. Thyroid Nodules and Cancer

Bulges that develop inside the thyroid gland are called thyroid nodules. Although benign nodules predominate, some may be malignant and result in thyroid cancer.

- Thyroid Nodules:** These may be benign (cysts and colloid nodules) or malignant (follicular or papillary cancer).
- Thyroid Cancer:** Mostly referring to follicular and papillary thyroid carcinomas, this term describes cancerous growths inside the thyroid gland.^[16,17,18]

DIAGNOSIS

Pregnancy-related thyroid problems provide special diagnostic challenges because of fetal safety concerns and physiological changes. The present review delineates the diagnostic methodology for thyroid illness in expectant mothers, underscoring the significance of precise evaluation and prompt management.

Clinical Assessment

History and Physical Examination

- The diagnosis approach is guided by a comprehensive medical history that includes prior thyroid diseases, family history, and present symptoms. Signs of goiter, palpable nodules, or symptoms indicative of hyper- or hypothyroidism may be found on physical examination.

Laboratory Testing

1. Thyroid Function Tests (TFTs)

- **Serum Thyroid-Stimulating Hormone (TSH):** TSH, or serum thyroid-stimulating hormone, is a hormone that indicates hypothyroidism when levels are high and hyperthyroidism when levels are low.
- **Free Thyroxine (T4) and Triiodothyronine (T3):** Measure the levels of free hormones; because pregnancy alters thyroid-binding proteins, free T4 is favored over total T4.

2. Thyroid Antibody Testing

- **Thyroid Peroxidase Antibodies (TPOAb) and Thyroglobulin Antibodies (TgAb):** Increased levels indicate autoimmune thyroid illness, which helps diagnose Graves' disease or Hashimoto's thyroiditis.

3. Thyroid Ultrasound

This non-invasive imaging method visualizes the thyroid gland by using sound waves. evaluates the size, vascularity, nodules, and shape of the thyroid.

4. Fine-Needle Aspiration Biopsy (FNAB) for Nodules:

Invasive process that includes removing cells from thyroid nodules using a fine needle so they can be examined under a microscope. establishes the benignity or malignancy of nodules.^[19,20,21]

TREATMENT OF HYPOTHYROIDISM DURING PREGNANCY

Pregnancy-related hypothyroidism must be carefully managed to protect the health of both the mother and the fetus. This article provides a thorough analysis of the several approaches to treating hypothyroidism in pregnant women, including drug types and doses.

1. Levothyroxine Replacement Therapy Treatment Approach

- **Initiation:** The mainstay of therapy for hypothyroidism in pregnancy is levothyroxine..
- **Dosage Initiation:** Generally started at pre-pregnancy dosages or determined by weight and hypothyroidism severity.
- **Trimester-Specific Dosing:** Due to physiological changes and higher thyroid hormone needs during pregnancy, adjustments may be required.

Dosage Guidelines

- **Pre-Pregnancy Dosage:** 1.6–1.8 mcg/kg/day is commonly used as the starting point for pre-pregnancy dosages.
- **Monitoring:** To ensure euthyroidism and guide dose modifications, thyroid function tests (TSH and free T4) should be routinely monitored every 4-6 weeks.

2. Considerations for Dosage Adjustment Trimester-Specific Reference Ranges

- **First Trimester:** Target TSH <2.5 mIU/L in the first trimester; dose modifications may need a 25–30% increase over pre-pregnancy levels.
- **Second Trimester:** In the second trimester, target a TSH of less than 3 mIU/L; dose modifications might be more cautious, including a 10–20% rise.
- **Third Trimester:** A further 10–20% increase in dose may be necessary to achieve the target TSH of less than 3.5 mIU/L.

Individualized Approach

- Modifications must be based on the patient's clinical condition, thyroid function, and reaction to therapy.
- Regular monitoring is essential to avoid under- or over-treating, which can have a negative impact on the health of the mother and the fetus.

3. Management of Autoimmune Thyroiditis (Hashimoto's Thyroiditis)

Levothyroxine Initiation

- Levothyroxine medication must be started right away in order to restore euthyroidism and reduce dangers to the growing fetus.
- Clinical symptoms and thyroid function testing dictate treatment, and treatment is closely monitored during pregnancy.

4. Iodine Supplementation

- Supplementation may be necessary in iodine-deficient areas to prevent iodine insufficiency in both the mother and the fetus; however, excessive iodine consumption should be avoided since it may worsen thyroid dysfunction, especially in the context of autoimmune thyroiditis.

5. Management of Subclinical Hypothyroidism

- The best way to treat subclinical hypothyroidism during pregnancy is still up for dispute. Some recommendations recommend levothyroxine medication if TSH levels are higher than trimester-specific reference limits or if thyroid autoimmunity is present.^[22,23,24]

TREATMENT OF HYPERTHYROIDISM DURING PREGNANCY

Pregnancy-related hyperthyroidism management calls for a sophisticated strategy to balance the thyroid function of the mother with the health of the fetus. This article offers a thorough summary of the several approaches of treating hyperthyroidism in pregnant women, along with recommended drug types and doses.

1. Antithyroid Medications

1.1 Propylthiouracil (PTU)

- **Treatment Approach:** Because it has a decreased risk of congenital abnormalities, it is thought to be

the best antithyroid medication during the first trimester.

- **Dosage Initiation:** Depending on the mother's thyroid function, dosages are usually begun at 100–150 mg every eight hours.
- **Monitoring:** Due to the possibility of hepatotoxicity, regular evaluation of liver function tests and thyroid function tests (TSH, free T4).

1.2 Methimazole (MMI)

- **Treatment Approach:** Preferred beyond the first trimester, but has a somewhat increased risk of fetal abnormalities in comparison to PTU.
- **Dosage Initiation:** Depending on the mother's thyroid function, dosages are often started at 5–10 mg every 8–12 hours.
- **Monitoring:** Thyroid and liver function tests need to be regularly monitored, just as PTU.

2. Beta-Blockers

2.1 Propranolol

- **Symptomatic Management:** This approach reduces the symptoms of hyperthyroidism, including tremors, palpitations, and heat sensitivity.
- **Dosage Initiation:** 10–20 mg every 6–8 hours is the usual starting point, however care is advised owing to the possibility of fetal growth restriction and neonatal hypoglycemia.
- **Monitoring:** Frequent evaluation of the health of the mother and fetus, especially in the third trimester.

3. Definitive Therapy

3.1 Radioactive Iodine (RAI) Therapy

- **Considerations:** Because of the teratogenic effects on the fetus and possible harm to the fetal thyroid gland, it is generally not recommended during pregnancy.
- **Timing:** When feasible, postpone until after delivery to reduce dangers to the developing foetus.

3.2 Surgery (Thyroidectomy)

- **Indication:** Saved for patients with severe hyperthyroidism or those who are not responding to medical treatment.
- **Timing:** To reduce the risk of miscarriage and premature labor, it is best to do this procedure in the second trimester.^[25,26,27]

TREATMENT OF THYROIDITIS DURING PREGNANCY

In order to relieve symptoms and avoid problems while maintaining the health of the mother and fetus, thyroiditis during pregnancy has to be carefully managed. This study examines several approaches to treating thyroiditis in pregnant women, such as medication and therapy

1. Symptomatic Management

1.1 Beta-Blockers

- **Treatment Approach:** Applied to reduce thyrotoxicosis symptoms including tremors and palpitations.
- **Common Drugs:** Propranolol, atenolol, and metoprolol.
- **Dosage:** Based on maternal heart rate and symptom control, modest dosages were initially administered and then increased.

2. Levothyroxine Replacement Therapy

2.1 Hypothyroid Phase

- **Treatment Approach:** If the hypothyroid phase lasts, levothyroxine may be started.
- **Dosage:** Started at prenatal dosages or modified in accordance with thyroid function tests conducted on the mother.

3. Anti-Inflammatory Therapy

3.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

- **Treatment Approach:** Applied to reduce inflammation and discomfort in subacute thyroiditis.
- **Common Drugs:** Ibuprofen, naproxen, and aspirin.
- **Dosage:** Given for the shortest amount of time at the lowest effective dose.

4. Symptomatic Relief Measures

4.1 Pain Management

- **Treatment Approach:** Non-pharmacological methods such as warm compresses and analgesics may provide relief from thyroid pain.
- **Medications:** In situations of subacute thyroiditis, acetaminophen may be administered to relieve discomfort.

5. Thyroid Hormone Suppression Therapy

5.1 Glucocorticoids

- **Treatment Approach:** Employed when there are severe symptoms or consequences associated with thyroiditis.
- **Mechanism:** Inhibits the production and release of thyroid hormones.
- **Dosage:** Given for a brief period of time at low to moderate dosages.

6. Supportive Measures

6.1 Rest and Hydration

- **Treatment Approach:** To promote healing and reduce symptoms, encourage getting enough sleep and staying hydrated.
- **Nutritional Support:** Make sure you're getting enough nutrients, especially if you're losing weight or have low appetite.^[28,29,30]

TREATMENT OF THYROID NODULES AND CANCER DURING PREGNANCY

Pregnancy-specific problems with thyroid nodules and cancer must be carefully managed to protect the growing

fetus while ensuring the health of the mother. This article offers a thorough summary of the several approaches of treating thyroid nodules and cancer in pregnant women, including drugs, surgery, and treatments.

1. Observation and Surveillance

1.1 Thyroid Nodules

- **Indication:** Benign, little nodules that were unintentionally found during pregnancy..
- **Approach:** Regular ultrasound monitoring combined with observation to track nodule development and size.
- **Monitoring:** As directed by a physician, thyroid ultrasounds should be performed on a regular basis every six to twelve months

2. Fine-Needle Aspiration Biopsy (FNAB)

2.1 Thyroid Nodules

- **Indication:** Unsettling ultrasonography findings or nodules that raise suspicions.
- **Approach:** FNAB is used to assess for cancerous growths or to direct further treatment.
- **Timing:** When used with the proper safety measures, it is deemed safe during pregnancy.

3. Surgery (Thyroidectomy)

3.1 Thyroid Cancer

- **Indication:** Thyroid cancer suspicion or confirmation necessitating immediate medical attention.
- **Timing:** Shouldn't be done right away, wait till after birth unless the malignancy is severe or shows symptoms.
- **Approach:** If surgery is determined to be required during pregnancy, a full or partial thyroidectomy is carried out in the second trimester.

4. Radioactive Iodine (RAI) Therapy

4.1 Thyroid Cancer

- **Indication:** Adjunctive therapy for the treatment of metastatic illness and ablation of remaining thyroid tissue after thyroidectomy.

- **Timing:** Because of the teratogenic effects on the fetus, it is generally not recommended during pregnancy.
- **Postpartum Consideration:** If RAI therapy is thought to be important for managing cancer, it may be considered after delivery.

5. Thyroid Hormone Replacement Therapy

5.1 Post-Thyroidectomy

- **Indication:** To maintain euthyroidism after thyroidectomy, start levothyroxine replacement treatment.
- **Timing:** Started surgically and modified in accordance with thyroid function examinations.

6. Considerations

6.1 Interdisciplinary Collaboration

- Collaboration of surgeons, oncologists, endocrinologists, and obstetricians in the development of an all-encompassing treatment strategy.
- Joint decision-making between the patient and the medical staff to assess the advantages and disadvantages of various treatment alternatives.

6.2 Fetal Safety

- When thinking about diagnostic and therapeutic procedures, taking into account potential teratogenic consequences and prenatal radiation exposure. Following safety regulations and taking preventative measures to reduce threats to the growing fetus.^[31,32,33]

Drugs Used to treat Thyroid disease in pregnancy

Drug Class	Examples	Mechanism of Action	Indication
Thyroid Hormones	Levothyroxine	Synthetic thyroid hormone replacement	Hypothyroidism
Antithyroid Agents	Propylthiouracil (PTU)	Inhibits thyroid hormone synthesis	Hyperthyroidism
	Methimazole (MMI)	Blocks thyroid hormone synthesis and release	Hyperthyroidism
Beta-Blockers	Propranolol	Blocks beta-adrenergic receptors, reduces symptoms of thyrotoxicosis	Symptomatic relief in hyperthyroidism
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	Ibuprofen, Naproxen	Reduces inflammation and pain associated with thyroiditis	Symptomatic relief in thyroiditis

COMPLICATIONS

Untreated thyroid illness during pregnancy may have serious consequences for the health of the mother and fetus, maybe even ending the pregnancy prematurely. Depending on the kind and degree of the thyroid condition, different consequences apply:

1. Hypothyroidism

- **Increased Risk of Pregnancy Complications:** Miscarriage, premature delivery, and prenatal hypertension are just a few of the unfavorable outcomes that have been linked to untreated hypothyroidism.
- **Neurodevelopmental Impact:** Severe or insufficiently treated maternal hypothyroidism can impact fetal neurodevelopment, resulting in cognitive deficits and reduced IQ in children.
- **Maternal Health Risks:** If left untreated, hypothyroidism can worsen symptoms in pregnant women, including depression, weight gain, and exhaustion, which can lower their quality of life and overall well-being.

2. Hyperthyroidism

- **Increased Risk of Maternal Complications:** Untreated hyperthyroidism increases the chance of maternal cardiovascular symptoms, such as palpitations and hypertension, getting worse and eventually leading to heart failure and preeclampsia.
- **Fetal Risks:** Preterm delivery, intrauterine fetal death, and fetal development restriction can all be caused by maternal hyperthyroidism, especially if it is severe or uncontrolled.
- **Neonatal Thyroid Dysfunction:** If maternal hyperthyroidism is left untreated, the baby may have transitory or permanent neonatal hyperthyroidism or hypothyroidism, which can impair thyroid growth and function.

3. Thyroid Nodules and Cancer

- **Malignancy Risk:** If thyroid cancer is left untreated during pregnancy, it might grow and spread, endangering the health of the mother and the fetus.
- **Diagnostic Challenges:** Due to the possibility of fetal radiation exposure, diagnostic tests such as fine-needle aspiration biopsies and radioactive iodine uptake scans may be postponed, making care of thyroid nodules during pregnancy more difficult.

4. Thyroiditis

- **Thyrotoxicosis Complications:** If left untreated, thyrotoxicosis, especially in cases of thyroiditis, can exacerbate symptoms including tachycardia, heat intolerance, and weight loss, which can negatively affect the quality of life and well-being of mothers.
- **Impact on Fetal Health:** Maternal thyroiditis may influence the growth and function of the fetus' thyroid, which may result in either a temporary thyroid malfunction in the newborn or long-term thyroid problems in the progeny.^[34,35,36]

FUTURE DIRECTIONS IN THE TREATMENT OF THYROID DISEASE DURING PREGNANCY

In order to enhance results for both the mother and the fetus, future directions in the treatment of thyroid illness during pregnancy will concentrate on improving current strategies and investigating cutting-edge therapies:

1. Personalized Medicine

- **Genomic Profiling:** Using genetic markers, this technique determines who is more likely to experience thyroid malfunction during pregnancy and adjusts treatment plans appropriately.
- **Precision Medicine:** Creation of individualized treatment plans based on traits unique to each patient, such as underlying thyroid disease, responsiveness to medication, and hereditary susceptibility.

2. Pharmacological Innovations

- **Novel Thyroid Hormone Analogs:** Development of novel thyroid hormone analogs for the treatment of hypothyroidism and thyroid hormone replacement therapy during pregnancy that have better bioavailability, stability, and effectiveness.
- **Targeted Antithyroid Medications:** Developed to treat hyperthyroidism in pregnancy, focused antithyroid drugs have better specificity and fewer side effects.

3. Immunomodulatory Therapies

- **Biological Agents:** Research is being done on biologic medicines that target certain pathways, such as B-cell and T-cell regulation, that are implicated in autoimmune thyroid disease in order to reduce inflammation and avoid thyroid dysfunction during pregnancy.
- **Immune Tolerance Induction:** Investigating immune tolerance induction techniques to lower the likelihood of autoimmune thyroid illness in progeny and stop maternal immunological reactions against fetal thyroid antigens.

4. Fetal Intervention

- **In Utero Thyroid Hormone Therapy:** Evaluation of in utero thyroid hormone supplementation to maximize fetal thyroid function and reduce the risk of neurodevelopmental problems in offspring born to mothers with thyroid dysfunction is known as "in utero thyroid hormone therapy."
- **Fetal Thyroid Imaging:** Developments in prenatal imaging methods have made it possible to evaluate the shape and function of the fetal thyroid, enabling the early identification of anomalies in the thyroid and prompt treatment.

5. Telemedicine and Remote Monitoring

- **Telehealth Platforms:** Especially in underserved or distant locations, the integration of remote monitoring devices and telemedicine platforms

might make it easier for pregnant women with thyroid illness to get specialist care.

- **Home Thyroid Function Testing:** Equipment for self-monitoring thyroid problems during pregnancy have been developed, allowing for remote management and real-time assessment..

6. Long-Term Follow-Up

- **Maternal and Offspring Cohort Studies:** These are longitudinal research projects aimed at evaluating the long-term effects of thyroid dysfunction in mothers on the health outcomes of their kids, their neurodevelopment, and their thyroid function in later life.
- **Transgenerational Effects:** Examination of the possible epigenetic changes and intergenerational thyroid disease transmission resulting from maternal thyroid dysfunction on offspring health.^[37 to 40]

CONCLUSOON

In conclusion, the overview of thyroid disease therapy during pregnancy emphasizes the significance of maximizing thyroid function in the mother while maintaining the safety and welfare of the developing baby. Achieving positive results during pregnancy requires the implementation of appropriate treatment measures that are particular to the type and degree of thyroid disease. Healthcare professionals are vital in monitoring mother thyroid health and directing treatment decisions, from the start of levothyroxine replacement therapy for hypothyroidism to the cautious titration of antithyroid drugs for hyperthyroidism. To effectively manage thyroid illness during pregnancy, obstetricians, endocrinologists, and other experts must work together in an interdisciplinary manner. Furthermore, there are encouraging opportunities to improve maternal and fetal outcomes and refine treatment strategies due to current research and personalized medicine breakthroughs. Healthcare professionals can successfully treat thyroid illness in pregnancy and enhance the health and well-being of both mother and baby by following evidence-based recommendations and providing individualized care.

REFERENCES

1. Alemu A, Terefe B, Abebe M, Biadgo B. Thyroid hormone dysfunction during pregnancy: A review. *Int J Reprod Biomed*, Nov. 2016; 14(11): 677-686.
2. De Escobar GM, Obregón MJ, del Rey FE. Maternal thyroid hormones early in pregnancy and fetal brain development. *Best Pract Res Clin Endocrinol Metab*, 2004; 18: 225–248.
3. Cignini P, Cafà EV, Giorlandino C, Capriglione S, Spata A, Dugo N. Thyroid physiology and common diseases in pregnancy: review of literature. *J Prenat Med.*, Oct. 2012; 6(4): 64-71.
4. Ferreira JL, Gomes M, Príncipe RM. Controversial Screening for Thyroid Dysfunction in Preconception and Pregnancy: An Evidence-Based Review. *J Family Reprod Health.*, Dec. 2020; 14(4): 209-220.
5. Negro R, Mestman JH. Thyroid disease in pregnancy. *Best practice & research. Clinical endocrinology & metabolism*, Dec. 2011; 25(6): 927–43.
6. Dulek H, Vural F, Aka N, Zengin S. The prevalence of thyroid dysfunction and its relationship with perinatal outcomes in pregnant women in the third trimester. *North Clin Istanb*, Sep. 2, 2019; 6(3): 267-272.
7. Hatch-McChesney A, Lieberman HR. Iodine and Iodine Deficiency: A Comprehensive Review of a Re-Emerging Issue. *Nutrients*, Aug. 24, 2022; 14(17): 3474.
8. Joshi JS, Shanoo A, Patel N, Gupta A. From Conception to Delivery: A Comprehensive Review of Thyroid Disorders and Their Far-Reaching Impact on Feto-Maternal Health. *Cureus*, Feb. 1, 2024; 16(2): e53362.
9. Lee SY, Pearce EN. Assessment and treatment of thyroid disorders in pregnancy and the postpartum period. *Nat Rev Endocrinol*, Mar. 2022; 18(3): 158-171.
10. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. *Physiol Rev.*, Apr., 2014; 94(2): 355-82.
11. Juneo F Silva, Natália M Ocarino, Rogéria Serakides, Thyroid hormones and female reproduction, *Biology of Reproduction*, November 2018; 99(5): 907–921.
12. Cignini P, Cafà EV, Giorlandino C, Capriglione S, Spata A, Dugo N. Thyroid physiology and common diseases in pregnancy: review of literature. *J Prenat Med.*, Oct. 2012; 6(4): 64-71.
13. Krassas GE, Poppe K, Glinoe D. Thyroid function and human reproductive health. *Endocrine Reviews.*, 2010; 31: 702–755.
14. McNeil AR, Stanford PE. Reporting Thyroid Function Tests in Pregnancy. *Clin Biochem Rev.*, Nov. 2015; 36(4): 109-26.
15. Moreno-Reyes R, Glinoe D, Van Oyen H, Vandevijvere S. High prevalence of thyroid disorders in pregnant women in a mildly iodine-deficient country: a population based study. *J Clin Endocrinol Metab.*, 2013; 98(9): 3694-3701.
16. Marx H, Amin P, Lazarus JH. Hyperthyroidism and pregnancy. *British Medical Journal.*, 2008; 336: 663–667.
17. McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. *Thyroid.*, 1992; 2: 155–159.
18. Momotani N, Noh J, Ishikawa N, et al. Relationship between silent thyroiditis and recurrent Graves' disease in the postpartum period. *Journal of Clinical Endocrinology and Metabolism.*, 1994; 79: 285–289.
19. Laurberg P, Andersen SL. Endocrinology in pregnancy: Pregnancy and the incidence, diagnosing and therapy of Graves'disease. *Eur J Endocrinol*, 2016; 175(5): R219-30.

20. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. *Thyroid*, 2003; 13(1): 3-126.
21. Pappa T, Anselmo J, Mamanasiri S, Dumitrescu AM, Weiss RE, Refetoff S. Prenatal diagnosis of resistance to thyroid hormone and its clinical implications. *J Clin Endocrinol Metab*, 2017; 102,10: 3775-3782.
22. Sahay RK, Nagesh VS. Hypothyroidism in pregnancy. *Indian J Endocrinol Metab*, May, 2012; 16(3): 364-70.
23. Fitzgerald PA, Tierny LM, McPhee SJ, Papadakis MA. *Current medical diagnosis and treatment*. 44th Ed. New York: McGraw-Hill; 2005. Endocrinology, 1102-1110.
24. Lazarus JH. Thyroid disorders associated with pregnancy: etiology, diagnosis, and management. *Treat Endocrinol*, 2005; 4: 31-41
25. Petca A, Dimcea DA, Dumitraşcu MC, Şandru F, Mehedintu C, Petca RC. Management of Hyperthyroidism during Pregnancy: A Systematic Literature Review. *J Clin Med.*, Feb. 24, 2023; 12(5): 1811.
26. Vadini, V., Vasistha, P., Shalit, A. *et al.* Thyroid storm in pregnancy: a review. *Thyroid Res.*, 2024; **17**: 2.
27. Goodwin TM, Hershman JM. Hyperthyroidism due to inappropriate production of human chorionic gonadotropin. *Clin Obstet Gynecol.*, 1997; 40: 32-44.
28. Bai, CF., Shen, GH., Yang, Y. *et al.* Subacute thyroiditis during early pregnancy: a case report and literature review. *BMC Pregnancy Childbirth*, 2022; **22**: 19.
29. Korevaar, T., Medici, M., Visser, T. *et al.* Thyroid disease in pregnancy: new insights in diagnosis and clinical management. *Nat Rev Endocrinol*, 2017; **13**: 610-622.
30. Biondi B, Cooper DS. Thyroid Hormone Suppression Therapy. *Endocrinol Metab Clin North Am.*, Mar. 2019; 48(1): 227-237.
31. Khaled H, Al Lahloubi N, Rashad N. A review on thyroid cancer during pregnancy: Multitasking is required. *J Adv Res.*, Jul. 2016; 7(4): 565-70.
32. Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The Diagnosis and Management of Thyroid Nodules: A Review. *JAMA*, Mar. 6, 2018; 319(9): 914-924.
33. Carballo M, Quiros RM. To treat or not to treat: the role of adjuvant radioiodine therapy in thyroid cancer patients. *J Oncol.*, 2012; 2012: 707156.
34. Tudosa R, Vartej P, Horhoianu I, Ghica C, Mateescu S, Dumitrache I. Maternal and fetal complications of the hypothyroidism-related pregnancy. *Maedica (Bucur)*, Apr. 2010; 5(2): 116-23.
35. Moore LE. Thyroid disease in pregnancy: A review of diagnosis, complications and management. *World J Obstet Gynecol*, 2016; 5(1): 66-72.
36. Tan TO, Cheng YW, Caughey AB. Are women who are treated for hypothyroidism at risk for pregnancy complications? *American Journal of Obstetrics and Gynecology*, 2006; 194: e1-e3.
37. Chen A, Luo Z, Zhang J, Cao X. Emerging research themes in maternal hypothyroidism: a bibliometric exploration. *Front Immunol*, Mar. 26, 2024; 15: 1370707.
38. Alexander EK. Moving From the Present to the Future—Elucidating the Association of Thyroid Dysfunction With Pregnancy Outcomes. *JAMA Netw Open*, 2022; 5(8): e2231009.
39. Moog NK, Entringer S, Heim C, Wadhwa PD, Kathmann N, Buss C. Influence of maternal thyroid hormones during gestation on fetal brain development. *Neuroscience*, Feb. 7, 2017; 342: 68-100.
40. Volterrani M, Sposato B. Remote monitoring and telemedicine. *Eur Heart J.*, Dec. 2019; 21(M): M54-M56.